Table 1.
MET targeting agents in lung cancer clinical trials
| Drug | Targets | Company | Phase | Combination | Line of treatment | Type of cancer | Trial status | Locations | ClinicalTrial.org number |
|---|---|---|---|---|---|---|---|---|---|
| Tivantinib (ARQ 197) |
MET (non-ATP competitive inhibitor) |
ArQule/Daiichi-Sankyo/Kyowa Hakko Kirin | II | Erlotinib | 2nd | Stage IIIB/IV NSCLC | Complete | International | NCT00777309 |
| II | Erlotinib | 2nd or 3rd | Stage IIIB/IV KRAS (+) NSCLC | Active | United States | NCT01395758 | |||
| III | Erlotinib | 2nd or 3rd | Stage IIIB/IV nonsquamous NSCLC | Active | International | NCT01244191 | |||
| III | Erlotinib | 2nd or 3rd | Stage IIIB/IV nonsquamous wild-type EGFR NSCLC | Active | Japan | NCT01377376 | |||
| Onartuzumab (MetMAb) |
MET (one-arm mAb) |
Genentech/Roche | II | Erlotinib | 2nd or 3rd | Advanced NSCLC | Active, not recruiting | – | NCT00854308 |
| III | Erlotinib | 2nd or 3rd | Stage IIIB/IV, MET IHC (+)NSCLC | Active | International | NCT01456325 | |||
| II | Gemcitabine + cisplatin/carboplatin | 1st | Stage IIIB/IV squamous | Not yet recruiting | – | NCT00854308 | |||
| II | Bevacizumab + platinum + paclitaxel/pemetrexed | 1st | Stage IIIB/IV nonsquamous NSCLC | Not yet recruiting | – | NCT01496742 | |||
| Crizotinib (PF-2341066) |
MET, ALK | Pfizer | I | PF-00299804 (pan-HER inhibitor) | – | Stage IIIB/IV NSCLC | Active | United States and Australia | NCT01121575 |
| I/II | Erlotinib | 2nd or 3rd | Stage IIIB/IV lung adenocarcinoma | Active | United States | NCT00965731 | |||
| III | None (open label, vs standard chemotherapy) | 2nd | NSCLC harbors ALK translocation | Active | International | NCT00932893 | |||
| III | None (open label, vs cisplatin/carboplatin + pemetrexed) | 1st | Nonsquamous NSCLC harbors ALK translocation | Active | International | NCT00932893 | |||
| Cabozantinib (XL184, BMS-907351) |
MET, VEGFR2, RET, KIT, AXL, FLT3 | Exelixis/Bristol-Myers Squibb | Ib/II | Erlotinib | – | Stage IIIB/IV NSCLC with disease progression on erlotinib (phase II) | Active, not recruiting | United States | NCT00596648 |
| II | None (open label, vs placebo) | – | Advanced malignancies including lung cancer | Active, not recruiting | International | NCT00940225 | |||
| Ficlatuzumab (AV-299) |
HGF Ab | AVEO Pharmaceuticals | Ib/II | Gefitinib | – | Asian patients with IIIB/IV lung adenocarcinoma (phase II) | Active, not recruiting | Asia | NCT01039948 |
| Foretinib (XL880, EXEL-2880, GSK1363089) |
MET, VEGFR2, AXL | Exelixis/GlaxoSmithKline | I/II | Erlotinib | 2nd or 3rd | Stage IIIB/IV NSCLC on erlotinib | Active | Canada | NCT01068587 |
| PF-04217903 | MET | Pfizer | I | None | – | Advanced cancer | Complete | – | NCT00706355 |
| SGX523 | MET | SGX Pharmaceuticals | I | None | – | Advanced cancer | Terminated | – | NCT00607399 |
| AMG 102 | HGF (HuMAb) |
Amgen | Ib/II | Cisplatin/etoposide | 1st | Extensive stage SCLC | Active, not recruiting | NCT00791154 | |
| I/II | Erlotinib | 2nd or 3rd | Stage IIIB/IV NSCLC | Active | United States | NCT01233687 | |||
| Amuvatinib (MP470) MGCD265 |
MET, c-KIT, PDGFR, FLT3 MET | Astex Pharmaceuticals MethylGene | II | Platinum/etoposide | 2nd or 3rd | SCLC | Active | United States and Poland | NCT01357395 |
| I/II | Erlotinib | 2nd or 3rd | Stage IIIB/IV NSCLC | Active | United States | NCT00975767 |
Abbreviations: Ab, antibody; ALK, anaplastic lymphoma kinase; ATP, adenosine triphosphate; FLT3, Fms-like tyrosine kinase 3; HER, human epidermal growth factor receptor; HGF, hepatocyte growth factor; IHC, immunohistochemistry; MAb, monoclonal antibody; NSCLC, nonsmall cell lung cancer; PDGFR, platelet-derived growth factor receptor; SCLC, small cell lung cancer; VEGFR2, vascular endothelial growth factor receptor 2; vs, versus.